Gcm Medical Group, Psc

San Juan 917

4 studies enrolling now · 24 studies all time

What they study most

Atopic Dermatitis, Cardiovascular Diseases, Chronic Migraine, Diabetes Mellitus, Type 2, Genital Psoriasis, Glomerulosclerosis, Focal Segmental, Hyperlipidemia, Hypertension, Interstitial Lung Diseases, Lupus Erythematosus, Systemic, Migraine, Nonalcoholic Fatty Liver Disease

Studies at this site

• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Recruiting now
• A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases — Recruiting now
• Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease — Recruiting now
• Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis — Recruiting now
• A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus — Running, not enrolling
• Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus — Enrolling by invitation
• A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) — Stopped early
• A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) — Completed
• Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis — Completed
• Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) — Completed
• An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis — Completed
• A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes. — Completed
• Evaluation of Galcanezumab in the Prevention of Chronic Migraine — Completed
• Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis — Completed
• Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study — Completed
• A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis — Completed
• A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes — Completed
• A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes — Completed
• A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus — Stopped early
• A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol — Stopped early
• A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes — Completed
• A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis — Completed
• A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus — Completed
• A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus — Stopped early